Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 6.322
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 497206230200.0
- FreeCF/Share 7.8498
- PFCF 26.0809
- PE 19.9526
- Debt/Assets 0.0331
- DivYield 0.0249
- ROE 0.3269
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
Read More
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company's talc products exposed her to asbestos and contributed to her developing mesothelioma, a cancer of the lining of the lungs. The verdict follows a 13-day trial in Ramsey County District Court, where jurors heard evidence that Johnson & Johnson sold and marketed talc-based co.
Read More
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Read More
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Read More
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
Read More
US FDA grants priority voucher to J&J's blood cancer treatment
Published: December 15, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products receiving an award under the program to 16 this year.
Read More
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
Read More
The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026
Published: December 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love S&P 500 dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.
Read More
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
Read More
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Read More
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
3 Dividend Stocks Wall Street is Piling Into Before 2026
Published: December 02, 2025 by: 24/7 Wall Street
Sentiment: Positive
There is an apparent shift in how Wall Street views the stock market, as retail investors are increasingly doubting the AI rally.
Read More
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
Read More
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Positive
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this customer relationship management software company because it enjoys a dominant market share and a wide competitive moat. We exited our position in nVent. It rallied on the prospect of increasing data center demand, pushing the stock above what we viewed as its fair value.
Read More
Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks
Published: December 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come.
Read More
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
Read More
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Read More
3 Smart Defensive Stocks for an Uneasy Market
Published: November 18, 2025 by: MarketBeat
Sentiment: Positive
At one point in early November, the Dow Jones Industrial Average (DJIA) briefly topped 48,000 for the first time ever. At different times in 2025, the NASDAQ and S&P 500 have made new all-time highs (ATHs).
Read More
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
Published: November 17, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm's disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics announced its acquisition by Johnson & Johnson (NYSE: JNJ) for $3.05 billion, marking a historic moment for the Vida III portfolio. Hald.
Read More
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global Therapeutic Area Head, Immunology for Janssen Pharmaceutical Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the biopharma analyst here at Wolfe.
Read More
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisition
Published: November 17, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company focused on developing targeted oral therapies for solid tumors, for $3.05 billion in cash. Halda's lead candidate, HLD-0915, is a once-daily oral therapy for prostate cancer that received FDA fast track designation in August 2025 following positive preliminary data from Phase 1/2 trials.
Read More
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
Published: November 17, 2025 by: Investors Business Daily
Sentiment: Neutral
Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good morning, everyone.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100